Acute lymphoblastic leukemia (ALL) with MLL/AF4 fusion is a common infant leukemia associated with a poor prognosis. 1 Research into the molecular mechanisms underlying ALL with MLL/AF4 has been hampered by the absence of a good animal model. Recently, two murine MLL/AF4 models (knock-in and inverter models) were established, in which the MLL/AF4 allele caused a B-cell lymphoma after a mean latency of at least 14 months, 2, 3 while another frequent MLL fusion, MLL/AF9 murine models developed in leukemia in a short latency (5-6 months). 4 There is thus a substantial discrepancy between the late onset of disease seen in murine MLL/AF4 models and very early onset seen in human infants. Another novel murine MLL/AF4 model (human-derived AF4 knock-in model by using Cre/Lox approach) showed MLL/AF4 induces acute leukemia in a short latency. 5 However, this model had a propensity toward acute myelogenous leukemia development, which differs from the strong association between MLL/AF4 and ALL in humans.
To develop a more similar murine MLL/AF4 model to human ALL with MLL/AF4, we established MLL/AF4 þ transgenic (Tg) mice by overexpression of human-derived MLL/AF4 fusion gene. MLL/AF4
þ Tg mice were established by microinjecting pMSCVneoMLL/AF4 (Figure 1a ) into the pronuclei of eggs from C57BL/6N Crj mice. The established MLL/AF4
þ Tg mice exhibited splenomegaly and lung tumors at 8-12 months of age (median, 12 months) (Figure 1b) , and histopathological and immunohistopathological analysis showed disruption of the spleen structure ( Figure 1c) and infiltration of the liver, lungs and spleen by CD45R/B220 þ CD3e À lymphoma cells (Figure 1d ). Infiltration of tumor cells into the peripheral blood was observed after a long latency period in MLL/AF4 þ Tg mice (median, 14 months) (Figure 1e ), at which time abnormal lymphocytes accounted for 7.2 ± 1.2% (n ¼ 5) of white blood cells. Fluorescence activated cell sorter analysis showed these abnormal lymphocytes to be CD45R/B220 (Figure 1f) , which is the same phenotype as the lymphoma cells. Thus, we generated a new MLL/AF4 Tg model mouse that overexpressed the human MLL/AF4 fusion protein, which in turn induced B-cell lymphoma in the liver, spleen and lungs. Although murine MLL/AF4 models have been described previously, 2,3,5 our MLL/AF4 Tg model mouse is the first examination of the potential of human MLL/AF4 fusion protein to induce B-cell lymphoma and/or leukemia, and pro-B-cells leukemic changes were observed. However, although leukemo-lymphomogenicity was observed in our Tg mice expressing the human MLL/AF4 fusion protein, the latency to disease onset was still much longer than in the human patients.
In an effort to develop a mouse model showing more aggressive oncogenesis, we have been focusing on Ras mutation as a factor that could explain discrepancy between murine model and human ALL with MLL/AF4. It is known, for example, that activating mutation of Ras gene and abnormalities in Ras signaling lead to uncontrolled growth factor-independent proliferation of hematopoietic progenitors. In addition, Liang et al. 6 reported that MLL-positive B-ALL is closely associated with Ras mutation (50%), especially with K-Ras mutation (40%), whereas MLL-positive acute myeloid leukemia is not. Therefore,
Tg mice by crossing the newly established MLL/AF4
þ Tg mice and K-Ras mutation þ Tg mice, which had an activated K-ras G12D . 7 We then used these mice to determine whether the combination of K-Ras mutation and the MLL/AF4 fusion gene could produce the aggressive disease progression seen in cases of ALL with MLL/AF4 in humans. Figure 1g shows the leukemia/lymphoma-free survival (LFS) curves. In MLL/AF4 þ K-Ras mutation þ Tg mice, lymphoma or leukemia developed significantly earlier than in MLL/AF4 þ mice (median LFS: 5.5 months vs 12 months, P ¼ 0.001). Lymphoma or leukemia also developed significantly earlier in MLL/AF4 þ K-Ras mutation þ Tg mice than in K-Ras mutation þ mice (median LFS: 5.5 months vs not reached, Po0.001).
Histopathological analysis showed that infiltration of lymphoma cells and destruction of normal organ structure occurred in the liver, lung and spleen, and immunohistochemical analysis of each tissue showed that the phenotype of the lymphoma in MLL/AF4 þ K-Ras mutation þ Tg mice was similar to that in MLL/AF4
þ Tg mice (CD45R/B220 þ CD3e À ). Infiltration of tumor cells into the peripheral blood was observed after a short latency period in MLL/AF4 þ K-Ras mutation þ Tg mice (median age, 6 months), at which time leukemia cells accounted for 3.2 ± 0.9% (n ¼ 5) of white blood cells. Fluorescence activated cell sorter analysis showed these abnormal lymphocytes to be CD45R/B220 þ CD43 þ CD19 þ cells, which is the same phenotype as the lymphoma cells.
Here we found that K-Ras mutation is a potent factor contributing to the early onset of ALL with MLL/AF4. This is the first report of the apparent collaborative acceleration of leukemo-lymphomogenicity by MLL/AF4 and activated K-Ras in mice. With respect to the collaborative mechanism of MLL/AF4 and Ras mutation Ng et al. was found to occur via aberrant Hox expression and Raf activation both in vitro and in vivo.
9 These or similar mechanisms may contribute to the collaborative acceleration of leukemo-lymphomogenesis by MLL/AF4 and K-Ras in our mouse model.
As earlier studies showed that strong expression of HoxA9 was essential for acute leukemia with MLL, 10 we used western blotting to assess expression of HoxA9 in protein samples extracted from spleen of 14-month-old MLL/AF4
þ Tg mice and MLL/AF4 þ K-Ras mutation þ Tg mice. We found that expression of HoxA9 was upregulated in MLL/AF4
þ Tg mice (Figure 1h) . Moreover, expression of HoxA9 was much more upregulated in the MLL/AF4 þ K-RAS mutation þ Tg mice than those of MLL/AF4 þ Tg mice (Figure 1h ). Thus, MLL/ AF4 and activated K-Ras appear to act collaboratively to accelerate leukemo-lymphomogenicity in the MLL/AF4 þ K-Ras mutation þ Tg mouse model due to collaborative upregulation of HoxA9.
Recently, Bursen et al. 11 showed that, by itself, the AF4/MLL fusion protein was able to initiate the early onset of ALL without MLL/AF4, whereas MLL/AF4 was unable to initiate leukemogenesis in a mouse transplantation model. By contrast, our results indicate that MLL/AF4 is able to initiate the onset of ALL without AF4/MLL, though only after a long latency. This difference may reflect the expression of HoxA genes. A recent study showed the presence of two distinct subgroups of ALL cases with MLL/AF4: those with expression of HoxA genes and those without it. 12 Although we detected HoxA9 activation in our MLL/AF4 Tg mice, none of the observed leukemic phenotypes described by Bursen et al. included ectopic activation of HoxA genes. We, therefore, speculate that there are two subgroups of ALLs with MLL/AF4: one that is HoxA-independent and AF4/MLL-dependent and another that is HoxA-dependent and MLL/AF4-dependent and needs additional factors to accelerate the leukemogenicity.
In summary, we have succeeded in generating a novel MLL/AF4 þ K-Ras mutation þ Tg mouse, which develops B-cell lymphoma and/or leukemia with a relatively short latency (6 months), most likely due to collaborative acceleration of leukemo-lymphomogenesis. The collaborative acceleration of leukemo-lymphomogenesis seemed to be related to collaborative upregulation of HoxA9. We anticipate that the MLL/AF4
þ K-Ras mutation þ Tg mouse model will be useful
Letters to the Editor for studying the molecular mechanisms of MLL/AF4 leukemogenesis and for developing new therapies against MLL-related malignancies.
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The development of leukemia is a complex, multistep process that is not fully understood. Although many leukemias harbor chromosomal translocations and additional mutations that drive oncogenic transformation, non-genetic factors also contribute to leukemia development. We have demonstrated that the relative fitness of hematopoietic progenitor cells (HPC) has a major role in leukemogenesis. 1, 2 That is, the presence of normally functioning HPC can slow or eliminate leukemia development from a small pool of cells harboring an oncogene, whereas the presence of HPC that have impaired fitness enhances leukemogenesis. However, the importance of these findings seems to be underappreciated, perhaps because a clinically relevant model has not yet been demonstrated. We propose that a clinical correlate of our previous work is the development of treatmentrelated acute myelogenous leukemia (tAML) in patients who are treated with DNA-damaging agents, followed by myelosuppressive agents that impair the relative fitness of HPC. þ Tg mice. For immunopathological analysis, the pretreated slides were incubated for 60 min with anti-CD3e and anti-B220 primary antibodies. To visualize the anti-B220 binding, the slides were incubated for 30 min with FITC-conjugated anti-rat IgG and to visualize anti-CD3e binding, they were incubated with peroxidase-conjugated goat anti-rabbit IgG, after which the stain was developed using diaminobenzidine. Nuclei were counterstained with Mayer hematoxylin. Predominant CD45R/B220 þ B-cell lymphoma cells (fluorescent green) were observed. Arrows indicate B220-positive cells. (e) Wright-Giemsa staining of the peripheral blood (original magnification Â 100). Leukemia cells accounted for 7.2 ± 1.2% of white blood cells in the peripheral blood of 14-month-old MLL/AF4 
